KR100520985B1 - Hangover curing agent containing astaxanthin and aspartic acid - Google Patents
Hangover curing agent containing astaxanthin and aspartic acid Download PDFInfo
- Publication number
- KR100520985B1 KR100520985B1 KR10-2003-0022744A KR20030022744A KR100520985B1 KR 100520985 B1 KR100520985 B1 KR 100520985B1 KR 20030022744 A KR20030022744 A KR 20030022744A KR 100520985 B1 KR100520985 B1 KR 100520985B1
- Authority
- KR
- South Korea
- Prior art keywords
- hangover
- aspartic acid
- astaxanthin
- present
- releasing agent
- Prior art date
Links
- 206010019133 Hangover Diseases 0.000 title claims abstract description 63
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 44
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 44
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 44
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 44
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 44
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 title claims abstract description 40
- 235000003704 aspartic acid Nutrition 0.000 title claims abstract description 39
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 235000015872 dietary supplement Nutrition 0.000 abstract description 13
- 235000013376 functional food Nutrition 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 230000035622 drinking Effects 0.000 abstract description 7
- 235000019441 ethanol Nutrition 0.000 description 38
- 235000013305 food Nutrition 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000020510 functional beverage Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000816088 Papia Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000019997 soju Nutrition 0.000 description 2
- -1 sterol compounds Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002231 fructose derivatives Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055705 pangamic acid Drugs 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 108700024047 pangamic acid Proteins 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
- A23L31/10—Yeasts or derivatives thereof
- A23L31/15—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 아스타잔틴(astaxanthin) 및 아스파라긴산(aspartic acid)을 유효성분으로 함유하는 숙취해소제에 관한 것이다. 본 발명의 숙취해소제는 음주 후 혈중 알코올 농도를 감소시킬 뿐만 아니라 숙취 해소에 뛰어난 효과가 있으므로, 이를 음료나 식품 등의 기능성식품 및 건강보조식품에 사용될 수 있다.The present invention relates to a hangover resolver containing astaxanthin and aspartic acid as an active ingredient. Hangover releasing agent of the present invention not only reduces the blood alcohol concentration after drinking, but also has an excellent effect on resolving hangover, it can be used in functional foods such as drinks or foods and health supplements.
Description
본 발명은 아스타잔틴(astaxanthin) 및 아스파라긴산(aspartic acid)을 유효성분으로 함유하는 숙취해소제에 관한 것이다.The present invention relates to a hangover resolver containing astaxanthin and aspartic acid as an active ingredient.
알코올은 뇌의 억제중추를 마비하여 섭취시 외관상 흥분한 상태를 보여주는데, 의식과 동작을 억제하고 수면 및 마취 효과가 있어 스트레스를 많이 받는 현대인의 주요한 기호식품이다. 우리나라의 음주 문화는 경제성장과 함께 그 소비가 계속 증가하고 있고, 현재 개인당 알코올 소비 수준은 세계에서 최고 수준이다.Alcohol paralyzes the inhibitory center of the brain and shows an apparently excited state when ingested. It suppresses consciousness and movement, and has a sleep and anesthetic effect, which is a major favorite food for modern people who are stressed. Korea's drinking culture continues to grow with economic growth, and the current level of alcohol consumption per individual is the highest in the world.
그러나, 알코올은 과다 섭취하는 경우에 중독증으로 발전할 수 있고, 뇌 등의 중추신경계 뿐만 아니라 소화기관 및 간 등의 대사기관도 손상시키는 개인 건강을 위협하는 문제가 되고 있다. 또한, 음주운전 등으로 인한 교통사고의 증가는 사회적 문제로 크게 대두하고 있어, 알코올이 인체에 미치는 영향을 최소화 할 수 있는 식품이나 의약품 등에 대한 요구도 증가하고 있다.However, alcohol can develop into addiction when excessively ingested, and poses a threat to personal health that damages not only the central nervous system such as the brain, but also the metabolic organs such as the digestive system and the liver. In addition, the increase in traffic accidents due to drunk driving, etc. is emerging as a social problem, and the demand for foods or medicines that can minimize the effects of alcohol on the human body is also increasing.
음주 후 숙취 현상은 간세포에 축적된 에틸알코올 또는 아세트알데히드의 독성 작용에 의하여 발생되는 것으로, 상기 독성 작용이 장시간 지속되어 신진대사 등에 장애를 일으켜 발생된다. 구체적으로, 정상적인 에틸알코올 대사과정은 에틸알코올이 체내에 유입되면 위장 또는 소장에서 흡수되어 혈관 속으로 들어가 간장으로 이동하고, 간세포에는 알코올 탈수소효소가 있어 알코올을 아세트알데히드로 산화시키고, 상기 아세트알데히드는 간세포에 있는 아세트알데히드 탈수소효소에 의하여 초산을 분해되어 온 몸의 근육이나 지방조직으로 이행되어 최종적으로는 탄산가스와 물로 분해되는 것이다.The hangover phenomenon after drinking alcohol is caused by the toxic action of ethyl alcohol or acetaldehyde accumulated in hepatocytes, and the toxic action lasts for a long time, causing metabolism and the like. Specifically, in normal ethyl alcohol metabolism, when ethyl alcohol enters the body, it is absorbed by the gastrointestinal or small intestine, enters the blood vessels, and moves to the liver. Acetic aldehyde dehydrogenase in hepatocytes leads to the breakdown of acetic acid into muscle and adipose tissue of the body, and finally into carbon dioxide and water.
또한, 상기 아세트알데히드 탈수소효소에는 아세트알데히드가 저농도인 경우에도 기능하는 Ⅱ형과 아세트알데히드가 고농도인 경우에만 작용하는 Ⅰ형이 있으나, 동양인은 일반적으로 Ⅱ형 아세트알데히드 탈수소효소가 결핍내지는 부족하기 때문에 아세트알데히드가 쉽게 분해되지 않는다. 따라서, 산화되지 아니한 아세트알데히드 및 에틸알코올의 유독 작용에 의하여 간세포와 뇌세포의 손상을 야기한다. 아울러, 알코올의 탈수작용으로 인한 체내의 수분 부족과 수분과 함께 여러 가지 전해질이 체외로 배출되어 전해질이 부족해진다. 상기 원인으로 인하여 정상적인 신진대사가 방해받아 구토, 두통, 오한, 복통 등의 다양한 숙취 현상이 발생하게 된다.In addition, the acetaldehyde dehydrogenase has a type II which functions even at low concentrations of acetaldehyde and a type I which functions only at high concentrations of acetaldehyde, but oriental people generally lack deficiency of type II acetaldehyde dehydrogenase. Acetaldehyde is not readily degraded. Therefore, damage of hepatocytes and brain cells is caused by the toxic action of unoxidized acetaldehyde and ethyl alcohol. In addition, various electrolytes are discharged to the outside of the body together with a lack of water and water due to the dehydration of alcohol, and the electrolyte is insufficient. Normal metabolism is disturbed due to the above causes, causing various hangovers such as vomiting, headache, chills and abdominal pain.
이러한 음주 후의 숙취 현상을 해소하기 위하여, 생약 제재 또는 인공 제재를 단독 또는 혼합하여 제조되는 다수의 숙취해소제가 개발되고 있으며, 민간에서는 북어국이나 콩나물국 등이 숙취해소에 자주 이용되고 있으나 보관이나 복용이 불편하여 이용에 한계가 있다. 따라서, 상기의 문제점을 해결하면서 경제적이고 효과가 탁월한 숙취해소제의 개발이 요구되고 있다.In order to solve the hangover phenomenon after drinking, a number of hangover medicinal products are prepared, which are prepared by mixing or using herbal medicines or artificial preparations. This inconvenience is limited to use. Therefore, while solving the above problems, there is a demand for the development of an economic and effective hangover relievers.
한편, 화학식 C40H52O4로 나타내어지는 아스타잔틴(astaxathin; 3,3'-dihydroxy-β,β-carotene-4,4'-dione)은 자연계에 광범위하게 분포하는 비타민 A의 전구물질인 베타카로틴으로 대표되는 카로티노이드 계열의 크산토필(xanthophyll)에 속하는 색소중의 하나이다(Di Mascio, P. et al. (1991) Am. J. Clin. Nutr., 53:194S-200S). 실제로 인간이 섭취하는 많은 식품에 존재하는 주홍색 또는 밝은 오렌지색의 색소인 아스타잔틴은 천연적으로 생산되어 해상 및 수상동물에 가장 널리 존재하고, 특히 새우, 붉은 도미류(red seabream), 연어(salmon) 및 바다가재(lobster) 등과 같은 해양 동물 조직에 존재하는 것으로 알려져 있다(Fujita, et al. (1983) Nippon Suisan Gakkaishi., 49:1855-1869; Johnson, E.A. (1991) Crit. Rev. Biotechnol., 11:297-326; Nelis, et al. (1991) J. Appl. Bacteriol., 70:181-191). 또한, 게나 가재를 삶으면 빨갛게 되는 것은 색소 단백질이 분해되어 붉은 아스타잔틴의 색이 나타나기 때문이다.On the other hand, astaxanthin represented by the formula C 40 H 52 O 4 (astaxathin; 3,3'-dihydroxy-β, β-carotene-4,4'-dione) is a precursor of vitamin A widely distributed in nature One of the pigments belonging to the carotenoid family of xanthophylls represented by phosphorus beta-carotene (Di Mascio, P. et al . (1991) Am. J. Clin. Nutr ., 53: 194S-200S). Indeed, astaxanthin, a vermilion or light orange pigment found in many human foods, is naturally produced and most widely found in marine and aquatic animals, especially shrimp, red seabream and salmon. ) And marine animal tissues such as lobsters (Fujita, et al . (1983) Nippon Suisan Gakkaishi ., 49: 1855-1869; Johnson, EA (1991) Crit. Rev. Biotechnol . , 11: 297-326; Nelis, et al . (1991) J. Appl. Bacteriol ., 70: 181-191). Also, boiled crabs and crawfish turn red because the pigment protein breaks down and the color of red astaxanthin appears.
또한, 생체 내에서는 단백질과 결합된 색소단백질로 많이 존재하는 아스타잔틴은 정상적인 호기적 대사과정 중 발생하는 활성 산소에 의한 세포 내 DNA, 단백질, 지질 등의 손상, 세포 및 조직의 노화와 발암을 유발하는 반응을 억제할 뿐만 아니라, 강력한 생물학적 항산화제로 강한 유리 라디칼(hydroxy or peroxy radicals)의 생성을 억제하는 작용을 하므로 지질의 과산화(peroxidation) 및 산화적 손상을 방지함으로써 LDL-콜레스테롤, 세포막 및 조직을 보호한다(Palozza et al. (1992) Arch. Biochem. Biophys., 297:291-295; Shimidzu, et al. (1996) Fish Sci., 62:134-137). 이것은 아스타잔틴이 단원자 산소를 제거시킬 수 있는 항산화력에서 비타민 E인 α-토코페롤(tocoperol) 보다 100 내지 500배 더 활성이 높고, β-카로틴보다는 10배 이상 더 강력한 항산화제 기능을 갖고 있기 때문이다.In addition, astaxanthin, which is a protein-linked pigment protein in vivo, damages DNA, proteins, lipids, etc., and aging and carcinogenesis of cells, tissues, and cells caused by free radicals generated during normal aerobic metabolism. In addition to suppressing the triggering reactions, it is a potent biological antioxidant that inhibits the production of strong hydroxy or peroxy radicals, thereby preventing LDL-cholesterol, cell membranes and tissues by preventing lipid peroxidation and oxidative damage. (Palozza et al . (1992) Arch. Biochem. Biophys ., 297: 291-295; Shimidzu, et al . (1996) Fish Sci ., 62: 134-137). Astaxanthin is 100-500 times more active than the vitamin E, α-tocoperol, and 10 times more potent than β-carotene in antioxidant capacity to remove monoatomic oxygen. Because.
한편, 여러 식품에 풍부하게 존재하는 아스파라긴산(C4H7O4N, CO2 H-CH(NH2)-CH2-CO2H)은 분자량은 133.10이고, 녹는점은 271℃인 단백질을 구성하는 아미노산의 한 종류로 아스파르트산 또는 아미노호박이라고도 한다. L-, D-형 2종의 이성질체가 있는데, 2-아미노숙신산(aminosuccinic acid)인 L형은 단백질을 구성하는 산성 아미노산이고, D형은 세균세포벽의 펩티도글리칸(peptideglycan) 및 바시트라신(bacitracin)의 성분이며 소나무에 유리산으로 존재한다. 1927년에 프리슨(Plisson, J.)이 아스파라거스 쥬스에서 처음 발견하였기 때문에 붙여진 이름이다. 사방정계(斜方晶系)에 속하는 무색의 판상 결정으로, 물과 알코올에는 녹지 않고 산 ·알칼리에는 녹는다.On the other hand, aspartic acid (C 4 H 7 O 4 N, CO 2 H-CH (NH 2 ) -CH 2 -CO 2 H), which is abundant in various foods, has a molecular weight of 133.10 and a melting point of 271 ° C. It is also called aspartic acid or amino zucchini as a kind of amino acid. There are two types of isomers, L- and D-types, in which L-type 2-aminosuccinic acid is an acidic amino acid constituting protein, and D-type is peptideglycan and bacitracin in bacterial cell wall. It is a component of (bacitracin) and exists as a free acid in pine. It was given its name because it was first discovered by Asparagus juice in 1927 by Plisson (J.). It is a colorless plate-like crystal belonging to the tetragonal system. It does not dissolve in water and alcohol but dissolves in acid and alkali.
아스파라긴산은 식물의 새싹에 많이 함유되어 있고, 중추신경계에 해로운 암모니아를 체내로부터 배출하는 기능을 돕는 것으로 널리 알려져 있으며 신진대사를 촉진하거나 정혈작용이 있다고 알려져 있다. 구체적으로 아스파라긴산은 뇌세포와 신경세포에 필요한 에너지원을 공급하고, 스테미나 증진시켜 피로, 우울증을 해소하고 대사에 중요한 역할을 한다. 또한, 세포의 에너지대사를 촉진하여 만성 피로증후군을 개선하는데 농도가 저하되면 우울증이 나타나지만, 농도가 너무 증가되면 간질이 나타난다. 아울러, 암모니아 대사를 촉진하여 간에 좋은 영양소가 되며, 다른 아미노산과 결합하여 독소를 흡수하여 혈액으로부터 제거하는 간해독 기능이 있다. 또한, 미네랄 흡수 보조 기능이 있어서, 어떤 종류의 미네랄의 장흡수를 도와서 미네랄의 혈중농도를 높임으로서 세포의 기능을 돕고, 유전정보를 전달하는 DNA와 RNA의 기능을 강화한다. 나아가, 면역글로불린과 항체생성을 촉진하여 면역능을 강화시키는 작용이 있다. Aspartic acid is found in many plant buds, and is widely known to help the body release ammonia, which is harmful to the central nervous system. Specifically, aspartic acid supplies energy sources for brain cells and nerve cells, and enhances stamina to relieve fatigue and depression and plays an important role in metabolism. In addition, by promoting energy metabolism of the cell to improve chronic fatigue syndrome, when the concentration is lowered, depression appears, but when the concentration is too high, epilepsy appears. In addition, it promotes ammonia metabolism to become a good nutrient to the liver, and has a liver detoxification function that combines with other amino acids to absorb the toxin to remove from the blood. In addition, there is a mineral absorption assistance function, to help the absorption of any kind of minerals to increase the blood concentration of minerals to help the function of the cell, and to enhance the function of DNA and RNA to transmit genetic information. In addition, there is an action to enhance immune function by promoting the production of immunoglobulins and antibodies.
이에, 본 발명자들은 아스타잔틴 및 아스파라긴산을 함유하는 숙취해소제가 숙취, 기타 질환의 개선 및 혈중 알코올 농도를 감소시키는 효능이 있어 숙취해소용 기능성식품이나 건강보조식품에 사용될 수 있음을 밝힘으로써 본 발명을 완성하였다.Accordingly, the present inventors have revealed that the hangover releasing agent containing astaxanthin and aspartic acid can be used in hangovers and other foods and health supplements because it has the effect of improving hangover and other diseases and reducing blood alcohol concentration. Was completed.
본 발명은 상기와 같은 요구에 의하여 안출된 것으로서, 본 발명의 목적은 아스타잔틴 및 아스파라긴산을 주성분으로 함유하는 숙취해소제를 제공하는 것이다. The present invention has been made in view of the above requirements, and an object of the present invention is to provide a hangover releasing agent containing astaxanthin and aspartic acid as a main component.
상기 목적을 달성하기 위하여, 본 발명은 아스타잔틴을 함유하는 숙취해소제를 제공한다.In order to achieve the above object, the present invention provides a hangover relief agent containing astaxanthin.
또한, 본 발명은 상기 숙취해소제를 함유하는 경구형 제제를 제공한다. The present invention also provides an oral preparation containing the hangover relieving agent.
또한, 본 발명은 상기 숙취해소제를 함유하는 기능성식품 또는 건강보조식품을 제공한다.In addition, the present invention provides a functional food or health supplement containing the hangover releasing agent.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 아스타잔틴을 함유하는 숙취해소제를 제공한다. 상기 숙취해소제는 아스타잔틴 및 아스파라긴산을 함유하는 것이 바람직하고, 총중량을 기준으로 아스타잔틴 0.01-0.1 중량%와 아스파라긴산 1-5 중량%을 함유하는 것이 가장 바람직하다. 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고 사용되는 식품의 종류이나 섭취량에 따라 변할 수 있다. The present invention provides a hangover relief agent containing astaxanthin. The hangover relievers preferably contain astaxanthin and aspartic acid, most preferably 0.01-0.1 wt% astaxanthin and 1-5 wt% aspartic acid based on the total weight. The composition as described above is not necessarily limited thereto, and may vary depending on the type or intake of food used.
본 발명에서는 현재까지 음주 후 숙취 해소 및 혈중 알코올 농도 감소 등의 효능에 대해서 알려진 바가 없는 아스타잔틴을 혈중 알코올 농도를 감소시켜 숙취 해소 용도로 사용하는 것을 특징으로 한다. 특히, 상기 아스타잔틴과 함께 알코올 대사를 촉진시키는 아스파라긴산을 혼합한 것은 그 효과가 매우 뛰어나다. 본 발명의 숙취해소제는 아스타잔틴을 단독으로 사용하거나 또는 아스파라긴산을 단독으로 사용했을 때 보다 혈중 알코올 감소 효능의 숙취 해소 효과가 뛰어나다.In the present invention, astaxanthin, which has not been known about the effects such as hangover resolution and blood alcohol concentration reduction until now, is used for reducing hangover by reducing blood alcohol concentration. In particular, the combination of astaxanthin and aspartic acid for promoting alcohol metabolism is very effective. Hangover releasing agent of the present invention is superior to the hangover relief effect of blood alcohol reduction effect than when using astaxanthin alone or aspartic acid alone.
본 발명의 아스타잔틴 및 아스파라긴산을 유효성분으로 함유하는 숙취해소제에 있어서, 아스타잔틴은 공지의 방법으로 제조될 수 있는데 본 발명에서는 대한민국 공개특허공보 제2001-44210호에 기재된 방법에 따라 제조하였다. 상기의 방식으로 제조한 아스타잔틴을 아스파라긴산과 혼합하여 본 발명의 숙취해소제를 제조할 수 있다.In the hangover releasing agent containing astaxanthin and aspartic acid of the present invention as an active ingredient, astaxanthin may be prepared by a known method, but in the present invention, it is prepared according to the method described in Korean Patent Laid-Open No. 2001-44210. It was. Astaxanthin prepared in the above manner can be mixed with aspartic acid to prepare the hangover releasing agent of the present invention.
본 발명의 숙취해소제에는 상기 아스타잔틴 및 아스파라긴산의 주요성분 이외에 보조성분이나 공지된 첨가제로 비타민 A, D, C, B, E 또는 K, Ca, Mg, Fe, Cu, Zn, Mn, Mo, Co, I, F, P 등의 미네랄 함유 화합물이나 레시틴 등의 인지질, β-시토스페롤 등의 스테롤 화합물, 구연산, 구연산나트륨, 사과산, 레시틴, 아미노산, 판감산(pangamic acid), 백설탕, 과당, 천연향료, 천연색소 등의 화합물을 사용할 수 있으며, 이중에서도 비타민 C, E와 Ca, Zn, 레시틴, 구연산, 판감산으로 이루어진 군에서 선택되는 2-4 성분을 함유하는 것이 더욱 바람직하다. 이때, 천연향료로는 장미향, 레몬향, 바닐라향 또는 박하향 등과 같은 물질일 수 있으며, 천연색소로는 클로로필린(chlorophyllin), 플라보노이드(flavonoid) 등과 같은 물질일 수 있으며, 백설탕 등 대신에 글루코오스, 벌꿀 등으로 감미성분을 대신할 수 있다. Hangover releasing agent of the present invention, vitamin A, D, C, B, E or K, Ca, Mg, Fe, Cu, Zn, Mn, Mo as auxiliary components or known additives in addition to the main components of the astaxanthin and aspartic acid Mineral-containing compounds such as, Co, I, F and P, phospholipids such as lecithin, sterol compounds such as β-sitosperol, citric acid, sodium citrate, malic acid, lecithin, amino acids, pangamic acid, white sugar, fructose Compounds such as natural fragrances and natural pigments may be used, and more preferably, 2 to 4 components selected from the group consisting of vitamins C, E and Ca, Zn, lecithin, citric acid and panic acid. At this time, the natural flavor may be a substance such as rose flavor, lemon flavor, vanilla flavor or peppermint flavor, and the natural pigment may be a substance such as chlorophyllin, flavonoid, etc., instead of white sugar, glucose, honey, etc. It can be replaced with sweet ingredients.
또한, 본 발명은 상기 숙취해소제를 함유하는 경구형 제제를 제공한다.The present invention also provides an oral preparation containing the hangover relieving agent.
이때, 상기 경구형 제제는 정제, 환제, 산제, 과립제, 캡슐제 및 액제로 이루어진 군 중에서 선택된 것임이 바람직하다.At this time, the oral preparation is preferably selected from the group consisting of tablets, pills, powders, granules, capsules and liquids.
즉, 본 발명의 아스타잔틴 및 아스파라긴산을 유효성분으로 함유하는 숙취해소제는 여러 가지 경구형 제제로 제조될 수 있는데, 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.In other words, the hangover releasing agent containing astaxanthin and aspartic acid of the present invention as an active ingredient can be prepared in various oral formulations, diluents such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. Or using excipients.
또한, 본 발명은 상기 숙취해소제를 함유하는 기능성식품 또는 건강보조식품을 제공한다.In addition, the present invention provides a functional food or health supplement containing the hangover releasing agent.
본 발명에 따른 아스타잔틴 및 아스파라긴산을 함유하는 숙취해소제를 기능성식품, 건강보조식품, 음료, 차 및 껌 등을 포함하는 각종 식품류 및 비타민 복합제에 첨가될 수 있다. Hangover releasing agent containing astaxanthin and aspartic acid according to the present invention can be added to various foods and vitamin complexes, including functional foods, dietary supplements, beverages, tea and gum.
상기에서 "건강보조식품"이란 건강보조의 목적으로 특정성분을 원료로 하거나 식품원료에 들어있는 특정성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말하며, "기능성식품"이란 식품성분이 갖는 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품을 말하는 것으로서, 질병의 예방 및 질병의 회복 등과 관련된 기능도 갖고 있는 것을 말한다. The term "health supplement" refers to a food prepared and processed by extracting, concentrating, refining, and mixing a specific ingredient as a raw material or contained in a food ingredient for the purpose of health supplement. Refers to foods that are designed and processed to fully exercise biological control functions such as biodefense, biorhythm control, disease prevention and recovery, etc. of food ingredients, and also functions related to disease prevention and disease recovery. Say what you have
본 발명의 아스타잔틴 및 아스파라긴산을 함유하는 숙취해소제를 기능성식품이나 건강보조식품에 사용할 경우, 상기 숙취해소제를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있음은 확실하다.When the hangover releasing agent containing astaxanthin and aspartic acid of the present invention is used in functional foods or health supplements, the hangover releasing agent may be added as it is or may be used together with other foods or food ingredients, and may be appropriately used according to conventional methods. Can be used. The blending amount of the active ingredient can be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). In general, in the case of long-term intake for the purpose of health and hygiene or health control in the manufacture of food or beverage, the amount may be below the above range, and there is no problem in terms of safety, so the active ingredient is It is evident that it can be used in more than a range.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.
본 발명의 숙취해소제는 종래의 일반적인 숙취해소제과는 달리 상기의 주요 유효성분의 혼합조성으로 인하여 상승작용을 가지기 때문에, 단순한 숙취제거 효과뿐만 아니라 혈중 알코올 농도의 감소 효과를 나타낸다. 아울러 상기의 숙취해소제에 기타 보조성분과 공지의 첨가제를 혼합하여 조성된 기능성 음료의 경우에 관능 검사를 실행한 결과, 그 선호도가 매우 높아서 다양한 종류의 기능성식품 또는 건강보조식품에 상기 숙취해소제가 이용될 수 있음을 확인하였다. The hangover releasing agent of the present invention has a synergistic effect due to the mixing composition of the main active ingredients, unlike the conventional hangover releasing agent, it exhibits not only a simple hangover removal effect, but also a blood alcohol concentration reduction effect. In addition, as a result of the sensory test performed in the case of the functional beverage prepared by mixing the other supplementary ingredients and known additives to the hangover remover, the hangover eliminating agent is applied to various kinds of functional food or health supplement food It was confirmed that it could be used.
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
<실시예 1> 아스타잔틴의 수득 Example 1 Obtaining Astaxanthin
본 발명자들은 대한민국공개특허 2001-44210의 방법에 따라 배양된 파피아 로드지마 균주로부터 색소를 추출하는 방식으로 아스타잔틴을 추출하였다.The present inventors extracted astaxanthin by extracting a pigment from the papia rodjima strain cultured according to the method of the Republic of Korea Patent Publication No. 2001-44210.
구체적으로, 파피아 로도지마 균주(수탁번호 KCTC 0921BP)를 5일간 배양하여 멸균수로 2회 세척한 후 물기를 제거하였다. 여기에 디메틸설폭사이드 1 ㎖, 아세톤 1 ㎖, 에테르 1 ㎖ 및 20% NaCl 용액 1 ㎖을 각각 순차적으로 첨가하여 교반한 후에 3, 000 rpm에서 5분 동안 원심분리하여 아스타잔틴을 추출하였다. 추출된 아스타잔틴을 희석하여 총중량의 0.05% 아스타잔틴 용액을 제조하여 하기의 실험을 수행하였다.Specifically, papia rhododoma strain (Accession No. KCTC 0921BP) was incubated for 5 days, washed twice with sterile water, and then dried. 1 ml of dimethyl sulfoxide, 1 ml of acetone, 1 ml of ether, and 1 ml of 20% NaCl solution were added sequentially and stirred, followed by centrifugation at 3,000 rpm for 5 minutes to extract astaxanthin. The extracted astaxanthin was diluted to prepare a 0.05% astaxanthin solution of the total weight, and the following experiment was performed.
<실시예 2> 아스파라긴산 용액의 제조Example 2 Preparation of Aspartic Acid Solution
아스파라긴산(미국 Austin Nutrional Research사에서 구입)을 증류에 희석하여 10 중량%인 아스파라긴산 스톡용액을 제조하였다. 상기 스톡용액을 희석하여 총중량의 3% 아스파라긴산 용액을 제조하여 하기의 실험을 수행하였다.Aspartic acid (purchased from Austin Nutrional Research, USA) was diluted in distillation to prepare a 10% by weight aspartic acid stock solution. The stock solution was diluted to prepare a total weight of 3% aspartic acid solution, and the following experiment was performed.
<실시예 3> 숙취해소제의 제조Example 3 Preparation of Hangover Relief
<3-1><3-1>
본 발명자들은 총 중량을 기준으로, 상기 실시예 1에서 추출된 아스타잔틴 및 실시예 2에서 제조한 아스파라긴산 스톡용액을 각각 희석하여 총중량을 기준으로 아스타잔틴 0.05 중량% 및 아스파라긴산 3 중량%를 함유하는 숙취해소제(정제수 96.95%)를 제조하였다.The present inventors dilute the astaxanthin extracted in Example 1 and the aspartic acid stock solution prepared in Example 2 based on the total weight, and contain 0.05% by weight of astaxanthin and 3% by weight of aspartic acid based on the total weight. Hangover relievers (purified water 96.95%) was prepared.
<3-2 내지 3-5><3-2 to 3-5>
중량% 만을 달리하여, 상기 실시예 <3-1>과 동일한 조성으로 각각 아스타잔틴 0.01 중량% 및 아스파라긴산 1 중량%(실시예 3-2), 아스타잔틴 0.1 중량% 및 아스파라긴산 5 중량%(실시예 3-3), 아스타잔틴 0.01 중량% 및 아스파라긴산 5 중량%(실시예 3-4), 및 아스타잔틴 0.1 중량% 및 아스파라긴산 1 중량%(실시예 3-5)를 함유하는 숙취해소제를 제조하였다.By varying only the weight%, 0.01% by weight of astaxanthin and 1% by weight of aspartic acid (Example 3-2), 0.1% by weight of astaxanthin and 5% by weight of aspartic acid in the same composition as in Example <3-1> Example 3-3) Hangover Relief containing 0.01% by weight of astaxanthin and 5% by weight of aspartic acid (Example 3-4), and 0.1% by weight of astaxanthin and 1% by weight of aspartic acid (Example 3-5) The agent was prepared.
<실시예 4> 숙취해소제의 혈중 알코올 농도에 미치는 영향Example 4 Effect of Hangover Relief on Blood Alcohol Concentration
본 발명자들은 실시예 1에서 추출된 아스타잔틴, 실시예 2에서 제조된 아스파라긴산, 아스타잔틴 및 아스파라긴산을 함유하는 상기 실시예 <3-1 내지 3-5>에서 제조된 숙취해소제를 실험 동물에 투여하여 본 발명의 숙취해소제가 실험 동물의 혈중 알코올 농도에 미치는 영향을 조사하였다.The inventors of the present invention, the astaxanthin extracted in Example 1, the aspartic acid prepared in Example 2, astaxanthin and aspartic acid containing the aspartic acid in the above-mentioned <3-1 to 3-5> experimental animals The effect of hangover releasing agent of the present invention on blood alcohol concentration of the experimental animals was investigated.
구체적으로 실험 동물은 3주 령의 스프래그-다우리(Sprague-Dawley) 랫트(대한 바이오링크(한국)에서 구입)를 사용하였고, 각 실험구 당 5 마리씩 음용수만 제공하고 24시간 절식시킨 후, 25% 에탄올을 상기 랫트 당 2㎖씩 스테인레스스틸 소식자(Sonde; 길이 10 ㎝)를 사용하여 강제 경구투여하였다. 1 시간 경과 후, 각 실험구에는 상기 <실시예 1>, <실시예 2> 또는 실시예 <3-1 내지 3-5>의 숙취해소제 2 ㎖을, 대조군에는 생리식염수 2 ㎖을 투여하고, 30분 경과 후에 상기 랫트의 심장으로부터 EDTA가 함유된 배큐테이너(vacutainer)에 혈액을 채취하였다. 상기 혈액에 함유되어 있는 에탄올 함량을 시그마(Sigma)사에서 구입한 키트(#332-UV)를 이용하여 측정하였다. 즉, 혈액 0.2 ㎖에 1.8 ㎖의 트리클로로아세트산(trichloroacetic acid)을 첨가하여 서서히 섞은 직후, 완전히 혼합하였다. 실온에서 5분 동안 방치한 후, 2,000 rpm에서 5분 동안 원심분리하고 상등액을 분리하였다. 10 ㎕의 상등액과 3 ㎖의 NAD+-NADH 용액을 조심스럽게 혼합하고, 실온에서 10분 동안 방치한 후, 색의 변화를 340 ㎚ 파장에서의 흡광도로 측정하였다.Specifically, the experimental animals used Sprague-Dawley rats (purchased from Daehan Biolink (Korea)) at 3 weeks of age, and provided only 5 water for each experiment and fasted for 24 hours, 25% ethanol was forced orally administered using 2 ml of stainless steel (Sonde; 10 cm in length) per rat. After 1 hour, 2 ml of hangover releasing agent of <Example 1>, <Example 2> or <3-1 to 3-5> was administered to each experimental section, and 2 ml of physiological saline was administered to the control group. After 30 minutes, blood was collected from the heart of the rat to a vacutainer containing EDTA. Ethanol content in the blood was measured using a kit (# 332-UV) purchased from Sigma. That is, 1.8 ml of trichloroacetic acid was added to 0.2 ml of blood, and mixed immediately after mixing. After standing at room temperature for 5 minutes, it was centrifuged at 2,000 rpm for 5 minutes and the supernatant was separated. 10 μl of supernatant and 3 ml of NAD + -NADH solution were carefully mixed and left at room temperature for 10 minutes before the change in color was measured by absorbance at 340 nm wavelength.
실험 결과를 하기 표 1에 기재하였고, 그 결과 본 발명의 숙취해소제는 가 에탄올 제거 효과가 탁월함을 확인하였다. The experimental results are shown in Table 1 below. As a result, the hangover releasing agent of the present invention confirmed that the ethanol removal effect was excellent.
주: 에탄올 농도는 상대적인 알코올 농도로서 100 = 0.92 ㎎ 에탄올/㎖ 혈액 Note: Ethanol concentration is relative alcohol concentration, 100 = 0.92 mg ethanol / ml blood
<실시예 5> 숙취해소제의 숙취 제거효과Example 5 Hangover Removal Effect of Hangover Relief
<5-1> 갈증해소, 두통제거<5-1> Quench your thirst and get rid of headaches
상기 실시예 <3-1 내지 3-5>에서 제조한 숙취해소제의 갈증해소와 두통제거 효과를 조사하였다. 구체적으로, 25 내지 50세의 남녀 각 10명을 선정하고 소주 150 ㎖ 및 맥주 200 ㎖을 섭취하게 한 다음 30분 후에 상기 실시예 <3-1 내지 3-5>의 숙취해소제 100 ㎖을 시음시킨 후 갈증해소와 두통제거 정도를 측정하였다. 그 결과를 하기 표 2에 기재하였으며, 본 발명의 숙취해소제가 갈증해소와 두통제거 효과가 탁월함을 확인하였다.The thirst quenching and headache elimination effects of the hanger relievers prepared in Examples <3-1 to 3-5> were investigated. Specifically, 10 men and women aged 25 to 50 years were selected and ingested 150 ml of soju and 200 ml of beer, and after 30 minutes, tasting 100 ml of hangover relieving agent of Examples 3 to 3-5. After quenching thirst and headache elimination was measured. The results are shown in Table 2 below, and it was confirmed that the hangover releasing agent of the present invention was excellent in quenching thirst and removing headache.
주: 양호 10점, 보통 5점, 효과 없음 0점Note: Good 10 points, normal 5 points, no effect 0 points
<5-2> 시간 경과에 따른 숙취 해소<5-2> Resolving Hangovers Over Time
알코올 대사에 이상이 없는 건강한 20~40대 남성 5명을 피검사로 선정하여 각각 30분 동안 소주 150 ㎖ 및 맥주 200 ㎖을 섭취하게 한 다음, 상기 실시예 1, 실시예 2 및 실시예 <3-1>에서 제조된 숙취해소제를 섭취하게 한 후, 매 10분 간격으로 알코올 농도, 맥박수 및 안색의 경시적 변화를 관찰하였다.Five healthy 20-40 males with no abnormalities in alcohol metabolism were selected as blood tests to ingest 150 ml of soju and 200 ml of beer for 30 minutes, respectively, followed by Examples 1, 2 and <3. After taking the hanger release agent prepared in -1>, the change in alcohol concentration, pulse rate and complexion was observed every 10 minutes.
알코올 농도는 음주측정용 알코올 탐지기로 측정하고, 맥박은 1분 동안의 박동수를 측정하였으며, 안색 변화는 5명의 관찰자를 별도 선정하여 안색 상태를 육안관찰하여 평균 점수를 도출하였다(안색 상태: 5점, 매우 홍조; 4점, 약간 홍조; 3점, 정상; 2점, 약간 창백; 1점, 매우 창백). 그 결과를 하기 표 3 내지 표 5에 기재하였다. Alcohol concentration was measured by alcohol detector for alcohol measurement, pulse was measured for 1 minute pulse rate, and the change of complexion was visually observed by five observers separately and the average score was derived (color state: 5 points). , Very flushing; 4, slight flushing; 3, normal; 2, slightly pale; 1, very pale). The results are shown in Tables 3 to 5 below.
그 결과, 상기 실시예 <3-1>의 방법으로 제조된 숙취해소제의 섭취 후 30분 내에 혈중 알코올 농도가 0.008% 이하로 떨어뜨리는 것을 확인하였으며, 맥박수와 안색도 빠르게 정상수치로 돌아와 본 발명의 숙취해소제가 알코올 대사능이 탁월하게 높음을 확인하였다.As a result, it was confirmed that the blood alcohol concentration dropped to 0.008% or less within 30 minutes after ingestion of the hangover releasing agent prepared by the method of Example <3-1>, the pulse rate and complexion also quickly returned to the normal value of the present invention. Hangover releasing agent was found to have a high alcohol metabolism.
<실시예 6> 상기 숙취해소제를 이용한 기능성 음료의 제조Example 6 Preparation of Functional Drink Using the Hangover Release Agent
<제조예 1> <Manufacture example 1>
아스타잔틴 0.05 중량%, 아스파라긴산 3 중량%, 비타민 C 0.1%, 과당 5.8%, 백설탕 3.87%, 구연산 0.12%, 사과산 0.03%, 구연산나트륨 0.04% 및 치자청색소 0.02%를 배합하여 계량된 물에 완전히 용해시켰다. 상기 용해된 음료를 총량이 100%(w/w %)가 되도록 계량된 정제수로 조정하였다.0.05% by weight of astaxanthin, 3% by weight of aspartic acid, 0.1% of vitamin C, 5.8% of fructose, 3.87% of white sugar, 0.12% of citric acid, 0.03% of malic acid, 0.04% of sodium citrate and 0.02% of gardenia blue pigment Completely dissolved. The dissolved beverage was adjusted with metered purified water such that the total amount was 100% (w / w%).
<제조예 2 내지 제조예 6> <Production Example 2 to Production Example 6>
하기 표 6에 기재된 바와 같이, 조성성분의 함량을 달리하는 것을 제외하고는 상기 제조예 1과 동일한 절차에 따라 제조예 2 내지 제조예 6의 기능성 음료를 제조하였다.As shown in Table 6 below, except for changing the content of the composition component was prepared in the functional beverage of Preparation Examples 2 to 6 according to the same procedure as in Preparation Example 1.
<실시예 7> 기능성 음료의 관능 검사Example 7 Sensory Evaluation of Functional Beverages
상기 실시예 6와 같이 제조한 제조예 1 내지 제조예 6의 기능성 음료에 대하여 관능검사요원 20명을 대상으로 하여 기호도에 대한 관능검사를 2회 반복 실시하였고, 그 결과를 하기 표 7에 기재하였다. 이때, 관능검사는 5점 척도법을 기준으로 하였다(1: 매우 나쁨, 2: 나쁨, 3: 보통, 4: 좋음, 5: 매우 좋음)For the functional beverages of Preparation Examples 1 to 6 prepared as in Example 6, the sensory test on the taste degree was repeatedly performed twice for 20 sensory test personnel, and the results are shown in Table 7 below. . The sensory test was based on the 5-point scale (1: very bad, 2: bad, 3: normal, 4: good, 5: very good).
상기 표 7의 시험결과를 통하여, 본 발명의 음료가 관능측면에서 선호할 수 있는 기능성식품으로 유용하게 사용될 수 있음을 확인하였다.Through the test results of Table 7, it was confirmed that the beverage of the present invention can be usefully used as a functional food that can be preferred in terms of sensory.
이상과 같이, 아스타잔틴 및 아스파라긴산을 포함하는 숙취해소제는 혈중 알코올 농도를 감소시키는 기능을 할 뿐만 아니라 상기 물질을 포함하는 기능성식품은 관능면에서도 선호할 수 있어서 숙취해소제로 유용하게 사용될 수 있다.As described above, hangover releasing agent containing astaxanthin and aspartic acid not only functions to reduce blood alcohol concentration, but functional foods containing the above substances may be preferred in terms of functionality, and thus may be usefully used as hangover releasing agents. .
상기에서 살펴본 바와 같이, 본 발명의 아스타잔틴 및 아스파라긴산을 함유하는 숙취해소제는 음주 후 혈중 알코올 농도를 감소 등의 숙취 해소에 뛰어난 효과가 있으므로, 음료나 식품 등의 기능성식품 및 건강보조식품에 사용될 수 있다.As described above, the hangover releasing agent containing astaxanthin and aspartic acid of the present invention has an excellent effect on resolving hangovers such as reducing blood alcohol concentration after drinking, and thus, for functional foods such as drinks and foods, and health supplement foods. Can be used.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2003-0022744A KR100520985B1 (en) | 2003-04-10 | 2003-04-10 | Hangover curing agent containing astaxanthin and aspartic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2003-0022744A KR100520985B1 (en) | 2003-04-10 | 2003-04-10 | Hangover curing agent containing astaxanthin and aspartic acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020050056189A Division KR100540498B1 (en) | 2005-06-28 | 2005-06-28 | Hangover curing agent containing astaxanthin and aspartic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040087808A KR20040087808A (en) | 2004-10-15 |
| KR100520985B1 true KR100520985B1 (en) | 2005-10-12 |
Family
ID=37369902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2003-0022744A KR100520985B1 (en) | 2003-04-10 | 2003-04-10 | Hangover curing agent containing astaxanthin and aspartic acid |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100520985B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101882791B1 (en) | 2017-12-26 | 2018-07-30 | (주)메디언스 | Food composition containing the extract of Zea mays L. with anthocyanin for healing a hangover |
| KR20230050601A (en) | 2021-10-08 | 2023-04-17 | 자람푸드 농업회사법인 주식회사 | Method of manufacturing hangover relieving drink using seaweed. |
-
2003
- 2003-04-10 KR KR10-2003-0022744A patent/KR100520985B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101882791B1 (en) | 2017-12-26 | 2018-07-30 | (주)메디언스 | Food composition containing the extract of Zea mays L. with anthocyanin for healing a hangover |
| KR20230050601A (en) | 2021-10-08 | 2023-04-17 | 자람푸드 농업회사법인 주식회사 | Method of manufacturing hangover relieving drink using seaweed. |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040087808A (en) | 2004-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101473017B1 (en) | Senescence inhibitor | |
| KR101301094B1 (en) | Composition for relieving hangover or improving liver function | |
| JP5705898B2 (en) | Liver function improving agent | |
| KR20110119305A (en) | A functional beverage comprising taurine, royal jelly, red ginseng, lycii fructus, glumate and apple essence as main ingredients | |
| JP6735224B2 (en) | Activator of glucose metabolism in astrocytes | |
| WO2004112510A1 (en) | Movement physiology improver | |
| KR20120044807A (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
| KR100540498B1 (en) | Hangover curing agent containing astaxanthin and aspartic acid | |
| KR100520985B1 (en) | Hangover curing agent containing astaxanthin and aspartic acid | |
| KR102433586B1 (en) | Food composition for relieving hangover and improving hepatic function | |
| KR100505764B1 (en) | Hangover curing agent containing astaxanthin, aspartic acid and extract from flowers of an arrowroot | |
| JP2003189816A (en) | Health food using plum fruit and plum seed kernel | |
| KR102235563B1 (en) | Composition for fatigue recovery and sexual function improvement containing high content of arginine | |
| KR20070033236A (en) | Liver function protectant containing ellagic acid, ellagitannin and natural plant extracts containing the same as active ingredients | |
| CN107362245A (en) | It is a kind of that there is the anti-oxidant and composition of reducing homosysteine | |
| KR20090007512A (en) | Emotional tea with spicy, sweety collagen blueberry vita green tea | |
| KR20140017933A (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
| KR20220085350A (en) | Hangover reliever comprising Codium extract or fraction thereof as an active ingredient | |
| KR101151339B1 (en) | Food composition for fatigue recovery or stress suppression comprising extract of reed-root, chinesequince and rice bran | |
| KR101221621B1 (en) | Food composition for fatigue recovery or stress suppression comprising extract of reed-root | |
| JP2004210675A (en) | Bone quantity amelioration composition | |
| KR100640094B1 (en) | Composition comprising the seed oil of Green Tea having Cholesterol-lowering or antioxidant activity | |
| KR100591791B1 (en) | Drink with usasge for anti-obeseness | |
| RU2769242C1 (en) | Ketogenic composition | |
| US8128969B2 (en) | Hypoglycemic composition containing acacia bark derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20120917 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20130829 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20141002 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20150909 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20161006 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20171011 Year of fee payment: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20180830 Year of fee payment: 14 |
|
| FPAY | Annual fee payment |
Payment date: 20190822 Year of fee payment: 15 |